Abstract
The objective of this study was to identify the most effective treatment by evaluating the different therapies used to treat mild, moderate, and severe Henoch–Schönlein purpura (HSP) patients. We performed a retrospective study of children discharged with a diagnosis of HSP. The study group consisted of 425 children divided into mild, moderate, and severe condition groups. Different therapeutic protocols of hydrocortisone sodium succinate (HCSS) therapy, methylprednisolone (MP) pulse therapy, and MP combination with tripterygium glycoside (TG) therapy were used to treat the different groups. The evaluation of curative effect was performed. After 4 weeks, all patients with no obvious recovery were treated by strengthening the different treatment intervention. The remission time of skin, joint, and gastrointestinal manifestations was evaluated, and the results of the follow-up were analyzed (remission time of proteinuria, relapse, and side effects of therapy). After 4 weeks, in the mild group, the difference of the curative effect between HCSS and MP therapy was not statistically significant. Moderate HSP patients were more likely to respond to MP therapy than HCSS therapy (P < 0.05). Severe HSP patients were more likely to respond to MP combination with TG than single MP therapy (P < 0.05). At last follow-up, they all had normal urinalysis. In the moderate HSP group, the mean duration of proteinuria was shorter in the MP pulse therapy group than in the HCSS therapy group (P < 0.05). In the mild group, the mean duration of purpura was shorter in HCSS therapy group than in the MP pulse therapy group (P < 0.05). At last follow-up, 99 patients had recurrences of purpura and/or proteinuria and 41 patients had liver functional impairment and/or hypertension. The relapse and side effects were all satisfactorily controlled, and the rates of relapse and side effects did not differ between groups with different therapies (P > 0.05). Our study has demonstrated a superior effect for HCSS therapy in patients with mild HSP disease, for MP therapy in patients with moderate disease, and for MP combined with TG therapy in patients with severe disease. MP therapy administered initially reduces the duration of urinary protein abnormality. The therapeutic protocols did not increase the risk of relapse and were safe.
Similar content being viewed by others
References
Saulsbury FT (2001) Henoch–Schönlein purpura. Curr Opin Rheumatol 13:35–40
Heberden W (1801) Commertarii de Malbaun. Historia et curatione, Payne, London
Schönlein JL (1837) Allgemenie und specielle Pathologie und Therapie, vol 2, 3rd edn. Herisau, Wurzburg
Henoch EH (1874) Uber eine eigentumliche Form von Purpura. Berliner Klinische Wochenschrift 2:641–643
Henoch EH (1895) Vorlesungen uber Kinderkrankheiten. Hirschwald, Berlin
Szer IS (2002) Henoch Schönlein purpura. Curr Opin Rheumatol 6:25–31
Ronkainen J, Nuutinen M, Koskimies O (2002) The adult kidney 24 years after childhood Henoch–Schönlein purpura: a retrospective cohort study. Lancet 360:666–670
Ronkainen J, Ala-Houhala M, Huttunen NP et al (2003) Outcome of Henoch–Schönlein nephritis with nephrotic-range proteinuria. Clin Nephrol 60:80–84
Goldstein AR, White RH, Akuse R et al (1992) Long-term follow-up of childhood Henoch–Schönlein nephritis. Lancet 339:280–282
Ozen S, Ruperto N, Dillon MJ et al (2006) EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 65:936–941
Peru H, Soylemezoglu O, Bakkaloglu SA et al (2008) Henoch Schönlein purpura in childhood: clinical analysis of 254 cases over a 3-year period. Clin Rheumatol 27:1087–1092
Trapani S, Micheli A, Grisolia F et al (2005) Henoch Schönlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 35:143–153
Chartapisak W, Opastiraku SL, Willis NS et al (2009) Prevention and treatment of renal disease in Henoch–Schönlein purpura: a systematic review. Arch Dis Child 94:132–137
Weiss PF, Feinstein JA, Luan X et al (2007) Effects of corticosteroid on Henoch–Schönlein purpura: a systematic review. Pediatrics 120:1079–1087
Ronkainen J, Koskimies O, Ala-Houhala M et al (2006) Early prednisone therapy in Henoch–Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr 149:241–247
Foster BJ, Bernard C, Drummond KN et al (2000) Effective therapy for severe Henoch–Schönlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. J Pediatr 136:370–375
Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein–Henoch purpura nephritis. Pediatr Nephrol 12:238–243
Shin JI, Park JM, Shin YH et al (2005) Can azathioprine and steroids alter the progression of severe Henoch–Schönlein nephritis in children? Pediatr Nephrol 20:1087–1092
Shenoy M, Bradbury MG, Lewis MA et al (2007) Outcome of Henoch–Schönlein purpura nephritis treated with long-term immunosuppression. Pediatr Nephrol 22:1717–1722
Tanaka H, Suzuki K, Nakahata T et al (2003) Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis. Pediatr Nephrol 18:347–350
Zheng CX, Chen ZH, Zeng CH et al (2008) Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney Int 74:596–612
Butani L, Morgenstern BZ (2007) Long-term outcome in children after Henoch–Schönlein purpura nephritis. Clin Pediatr (Phila) 46:505–511
Tarshish P, Bernstein J, Edelmann CM Jr (2004) Henoch–Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr Nephrol 19:51–56
Saulsbury FT (1999) Henoch–Schönlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore) 78:395–409
Calviño MC, Llorca J, García-Porrúa C et al (2001) Henoch–Schönlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study. Medicine (Baltimore) 80:279–290
Hari P, Bagga A, Jindal N et al (2001) Treatment of focal glomerulosclerosis with pulse steroids and oral cyclophosphamide. Pediatr Nephrol 16:901–905
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Deng, F., Lu, L., Zhang, Q. et al. Henoch–Schönlein purpura in childhood: treatment and prognosis. Analysis of 425 cases over a 5-year period. Clin Rheumatol 29, 369–374 (2010). https://doi.org/10.1007/s10067-009-1329-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-009-1329-2